Impellizeri Joseph A, Howell Kathy, McKeever Kathleen P, Crow Steven E
Sacramento Animal Medical Group, Cancer Treatment Center, 4990 Manzanita Avenue, Carmichael, CA 95608, USA.
Vet J. 2006 May;171(3):556-8. doi: 10.1016/j.tvjl.2005.03.005.
Targeting the CD20 receptor that is common to many B-cell Non-Hodgkin's Lymphoma subtypes in people, rituximab is a chimeric monoclonal antibody which has significantly improved disease-free survival rates compared with the use of cytotoxic agents alone. This study evaluated ex vivo canine B cell binding and depletion by rituximab with flow cytometric technique as possible proof of concept for treatment of canine lymphoma. Despite immunohistochemistry supporting CD20 expression, rituximab did not bind or deplete canine B cells and it is unlikely that it will be added to the armamentarium of treatment options for canine lymphoma.
利妥昔单抗靶向人类多种B细胞非霍奇金淋巴瘤亚型中常见的CD20受体，是一种嵌合单克隆抗体，与单独使用细胞毒性药物相比，它显著提高了无病生存率。本研究采用流式细胞术评估了利妥昔单抗对犬B细胞的体外结合和清除情况，作为治疗犬淋巴瘤的可能概念验证。尽管免疫组化支持CD20表达，但利妥昔单抗并未结合或清除犬B细胞，因此它不太可能被添加到犬淋巴瘤治疗方案的武器库中。
